85 Advanced Solid Tumors Clinical Trials in San Antonio, TX (2026)

Q: How do I join a clinical trial in San Antonio?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the San Antonio research site will contact you.

Recruiting Advanced Solid Tumors Studies in San Antonio

NCT05417594Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participan...

San Antonio, TXPHASE1695 participantsAstraZeneca

View Study Details

NCT06384352Recruiting

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evalu...

San Antonio, TXPHASE1500 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT06892379Recruiting

A Study of HS-20110 in Participants With Advanced Solid Tumors

This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors...

San Antonio, TXPHASE1475 participantsHansoh BioMedical R&D Company

View Study Details

NCT05458219Recruiting

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

This is a Phase Ia/Ib, multicenter, open-label, first-in-human study to evaluate the safety, tolerability, PK, and efficacy of IBI343 in participants with locally advanced unresectable or metastatic s...

San Antonio, TXPHASE1470 participantsInnovent Biologics (Suzhou) Co. Ltd.

View Study Details

NCT04665206Recruiting

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients wit...

San Antonio, TXPHASE1434 participantsVivace Therapeutics, Inc

View Study Details

NCT07094113Recruiting

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combin...

San Antonio, TXPHASE1434 participantsAmgen

View Study Details

NCT07197827Recruiting

A Study of YL242 in Subjects With Advanced Solid Tumors

This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors....

San Antonio, TXPHASE1424 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT05007782Recruiting

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS...

San Antonio, TXPHASE1416 participantsGilead Sciences

View Study Details

NCT06792552Recruiting

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors...

San Antonio, TXPHASE1414 participantsNextCure, Inc.

View Study Details

NCT05836324Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors....

San Antonio, TXPHASE1408 participantsIncyte Corporation

View Study Details

NCT06120283Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letro...

San Antonio, TXPHASE1399 participantsBeOne Medicines

View Study Details

NCT07397338Recruiting

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanc...

San Antonio, TXPHASE1370 participantsRevolution Medicines, Inc.

View Study Details

NCT07160725Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors...

San Antonio, TXPHASE1315 participantsBristol-Myers Squibb

View Study Details

NCT07136779Recruiting

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or...

San Antonio, TXPHASE1310 participantsVelaVigo Bio Inc

View Study Details

NCT07300943Recruiting

Study in Advanced Solid Tumor Patients

The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2...

San Antonio, TXPHASE1306 participantsCallio Therapeutics

View Study Details

NCT06952010Recruiting

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s...

San Antonio, TXPHASE1303 participantsExelixis

View Study Details

NCT06239194Recruiting

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors....

San Antonio, TXPHASE1285 participantsModeX Therapeutics, An OPKO Health Company

View Study Details

NCT05753722Recruiting

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors....

San Antonio, TXPHASE1270 participantsIncendia Therapeutics

View Study Details

NCT06752681Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in participants with advanced o...

San Antonio, TXPHASE1254 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT06979596Recruiting

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body...

San Antonio, TXPHASE2250 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06234397Recruiting

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and effic...

San Antonio, TXPHASE1245 participantsHanmi Pharmaceutical Company Limited

View Study Details

NCT05204862Recruiting

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

This study consists of Part A for monotherapy and Part B for combination therapy to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 in patients with advanced solid ...

San Antonio, TXPHASE1240 participantsTiumBio Co., Ltd.

View Study Details

NCT06413680Recruiting

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

This study is researching an experimental drug called REGN10597 (called "study drug"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study i...

San Antonio, TXPHASE1240 participantsRegeneron Pharmaceuticals

View Study Details

NCT07141706Recruiting

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes up t...

San Antonio, TXPHASE1233 participantsDualityBio Inc.

View Study Details

NCT05985655Recruiting

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617-001 in participants with advanced solid tumors....

San Antonio, TXPHASE1230 participantsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

View Study Details

NCT06577987Recruiting

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors....

San Antonio, TXPHASE1220 participantsCircle Pharma

View Study Details

NCT07060989Recruiting

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors....

San Antonio, TXPHASE1220 participantsNutshell Therapeutics (Shanghai) Co., LTD.

View Study Details

NCT06804824Recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-k...

San Antonio, TXPHASE1220 participantsVividion Therapeutics, Inc.

View Study Details

NCT06597721Recruiting

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as ...

San Antonio, TXPHASE1210 participantsAdcendo ApS

View Study Details

NCT07021898Recruiting

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ...

San Antonio, TXPHASE1200 participantsErasca, Inc.

View Study Details

NCT04219254Recruiting

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1...

San Antonio, TXPHASE1197 participantsBioInvent International AB

View Study Details

NCT07182591Recruiting

A Study of DS5361b in Participants With Advanced Solid Tumors

This study aims to assess the safety, tolerability, and preliminary efficacy and to determine the MTD of DS5361b in monotherapy and combination with pembrolizumab in participants with advanced or meta...

San Antonio, TXPHASE1192 participantsDaiichi Sankyo

View Study Details

NCT07169734Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P...

San Antonio, TXPHASE1180 participantsAlentis Therapeutics AG

View Study Details

NCT06956690Recruiting

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ENV-501 in Patients With HER3-Expressing Solid Tumors

This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of ENV-501 in patients with advanced-stage, relapsed...

San Antonio, TXPHASE1180 participantsEndeavor Biomedicines, Inc.

View Study Details

NCT07128303Recruiting

Study of GS-5319 in Adults With Solid Tumors

The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability in adults with solid tumors, where the participants show a specific gene alteration ...

San Antonio, TXPHASE1178 participantsGilead Sciences

View Study Details

NCT07601243Recruiting

Study of GS-2426 in Participants With Advanced Solid Tumors

The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tum...

San Antonio, TXPHASE1174 participantsGilead Sciences

View Study Details

NCT07266428Recruiting

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects tha...

San Antonio, TXPHASE1170 participantsOttimo Pharma Limited

View Study Details

NCT06265688Recruiting

First In Human Study of CX-2051 in Advanced Solid Tumors

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult pa...

San Antonio, TXPHASE1160 participantsCytomX Therapeutics

View Study Details

NCT05267626Recruiting

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be adminis...

San Antonio, TXPHASE1159 participantsAulos Bioscience, Inc.

View Study Details

NCT07612189Recruiting

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion po...

San Antonio, TXPHASE1155 participantsNEOK Bio, Inc.

View Study Details

NCT07612176Recruiting

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion p...

San Antonio, TXPHASE1155 participantsNEOK Bio, Inc.

View Study Details

NCT06532565Recruiting

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumor...

San Antonio, TXPHASE1154 participantsGilead Sciences

View Study Details

NCT07123103Recruiting

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion co...

San Antonio, TXPHASE1150 participantsExelixis

View Study Details

NCT07145255Recruiting

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment....

San Antonio, TXPHASE1150 participantsMBrace Therapeutics

View Study Details

NCT07124117Recruiting

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and putative recommended phase 2 dose of OBI-902 (study drug) as monotherapy. Part B (Cohort ...

San Antonio, TXPHASE1147 participantsOBI Pharma, Inc

View Study Details

NCT07605962Recruiting

Phase 1/2 Study of UI-102 in Selected Advanced Cancers

This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle....

San Antonio, TXPHASE1140 participantsUnited Immunity, co., Ltd.

View Study Details

NCT05784688Recruiting

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors....

San Antonio, TXPHASE1140 participantsTiumBio Co., Ltd.

View Study Details

NCT07360314Recruiting

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metas...

San Antonio, TXPHASE1138 participantsEMD Serono Research & Development Institute, Inc.

View Study Details

NCT05957536Recruiting

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

This first-in-human (FIH) study, multi-center, open-label, dose escalation and dose expansion Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunoge...

San Antonio, TXPHASE1128 participantsD3 Bio (Wuxi) Co., Ltd

View Study Details

NCT05841563Recruiting

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - s...

San Antonio, TXPHASE1125 participantsPharmaMar

View Study Details

NCT06723236Recruiting

A Study of MGC028 in Participants With Advanced Solid Tumors

The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defin...

San Antonio, TXPHASE1124 participantsMacroGenics

View Study Details

NCT06797336Recruiting

A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants wit...

San Antonio, TXPHASE1115 participantsPAQ Therapeutics, Inc.

View Study Details

NCT07213817Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the ...

San Antonio, TXPHASE1114 participantsIpsen

View Study Details

NCT07148128Recruiting

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours....

San Antonio, TXPHASE1110 participantsAuricula Biosciences Inc.

View Study Details

NCT06975293Recruiting

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalima...

San Antonio, TXPHASE1107 participantsSTORM Therapeutics LTD

View Study Details

NCT07416123Recruiting

A Study of GEN1106 in Participants With Solid Tumors

The purpose of this trial is to learn about the safety and effectiveness of GEN1106 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts. The f...

San Antonio, TXPHASE1103 participantsGenmab

View Study Details

NCT07213830Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new drug, IPN01203, in adults with advanced solid tumours. Advanced solid tumours are cancers that can ...

San Antonio, TXPHASE1102 participantsIpsen

View Study Details

NCT06507306Recruiting

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * ...

San Antonio, TXPHASE1100 participantsKumquat Biosciences Inc.

View Study Details

NCT06399757Recruiting

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus o...

San Antonio, TXPHASE1100 participantsApollo Therapeutics Ltd

View Study Details

NCT04762641Recruiting

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immu...

San Antonio, TXPHASE1100 participantsABL Bio, Inc.

View Study Details

NCT06803680Recruiting

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims ...

San Antonio, TXPHASE190 participantsBeOne Medicines

View Study Details

NCT06260514Recruiting

Study of APR-1051 in Patients With Advanced Solid Tumors

The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patient...

San Antonio, TXPHASE190 participantsAprea Therapeutics

View Study Details

NCT06799065Recruiting

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and pr...

San Antonio, TXPHASE190 participantsAccent Therapeutics

View Study Details

NCT07414836Recruiting

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants...

San Antonio, TXPHASE184 participantsBeOne Medicines

View Study Details

NCT05417321Recruiting

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors...

San Antonio, TXPHASE180 participantsShanghai Huaota Biopharmaceutical Co., Ltd.

View Study Details

NCT06730347Recruiting

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be e...

San Antonio, TXPHASE280 participantsMacroGenics

View Study Details

NCT07207707Recruiting

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it ai...

San Antonio, TXPHASE178 participantsKumquat Biosciences Inc.

View Study Details

NCT07166601Recruiting

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looki...

San Antonio, TXPHASE177 participantsEMD Serono Research & Development Institute, Inc.

View Study Details

NCT06672185Recruiting

ARC101 in Advanced Solid Tumors

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer....

San Antonio, TXPHASE170 participantsThird Arc Bio

View Study Details

NCT06297525Recruiting

Study of STP938 (Dencatistat) in Advanced Solid Tumours

The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy....

San Antonio, TXPHASE170 participantsStep Pharma, SAS

View Study Details

NCT06244992Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

This Phase 1/2a study will explore the safety and efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) activator, used alone or in combination with anti-PD-1/L1 therapy in patients with locally advanced or ...

San Antonio, TXPHASE168 participantsPyrotech Therapeutics, Inc.

View Study Details

NCT07181681Recruiting

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugate...

San Antonio, TXPHASE163 participantsBeOne Medicines

View Study Details

NCT07115043Recruiting

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors...

San Antonio, TXPHASE160 participantsAstraZeneca

View Study Details

NCT07086768Recruiting

Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

This is a study that will enroll patients with cancer who have tumors that may have spread. The patients will know what medication they are being given. There will be 2 parts to the study. For the fi...

San Antonio, TXPHASE157 participantsLei Zheng

View Study Details

NCT06600789Recruiting

A Modular Phase 1/2 Study with CT7439 in Participants with Solid Malignancies

This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in partici...

San Antonio, TXPHASE150 participantsCarrick Therapeutics Limited

View Study Details

NCT06959706Recruiting

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pha...

San Antonio, TXPHASE150 participantsTagworks Pharmaceuticals BV

View Study Details

NCT05868629Recruiting

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (1 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metasta...

San Antonio, TX40 participantsNovartis Pharmaceuticals

View Study Details

NCT07312903Recruiting

DPTX3186 in Wnt Pathway Activated Solid Tumors

This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial a...

San Antonio, TXPHASE140 participantsDewpoint Therapeutics

View Study Details

NCT07161414Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety...

San Antonio, TXPHASE140 participantsAstraZeneca

View Study Details

NCT07356453Recruiting

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-48 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or o...

San Antonio, TXPHASE140 participantsFoRx Therapeutics AG

View Study Details

NCT06750185Recruiting

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 i...

San Antonio, TXPHASE139 participantsBioNTech SE

View Study Details

NCT06504368Recruiting

Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treat...

San Antonio, TXPHASE132 participantsDicerna Pharmaceuticals, Inc., a Novo Nordisk company

View Study Details

NCT07705334Recruiting

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced ...

San Antonio, TXPHASE130 participantsSHY Therapeutics

View Study Details

NCT04617522Recruiting

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems....

San Antonio, TXPHASE130 participantsGilead Sciences

View Study Details

NCT07266285Recruiting

BTM-3566 in Advanced Solid Tumors

The goal of this clinical trial is to learn about what doses of BTM-356 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of BTM-3...

San Antonio, TXPHASE130 participantsBantam Pharmaceuticals

View Study Details

About Advanced Solid Tumors Clinical Trials in San Antonio

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 85 advanced solid tumors clinical trials recruiting participants in San Antonio, TX. These studies are seeking a combined 15,715 participants. Research is being sponsored by AstraZeneca, MediLink Therapeutics (Suzhou) Co., Ltd., Hansoh BioMedical R&D Company and 65 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in San Antonio — FAQ

Are there advanced solid tumors clinical trials in San Antonio?

Yes, there are 85 advanced solid tumors clinical trials currently recruiting in San Antonio, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Antonio?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Antonio research site will contact you about next steps.

Are clinical trials in San Antonio free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Antonio studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 85 active trials in San Antonio are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 22, 2026 from ClinicalTrials.gov